vTv Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview
07/03/2025 13:14
vTv Therapeutics Inc VTVT.OQ VTVT.O is expected to show no change in quarterly revenue when it reports results on March 11 (estimated) for the period ending December 31 2024 LSEG's mean analyst estimate for vTv Therapeutics Inc is for a loss of 87 cents per share. The one available analyst rating on the shares is "buy". The average consensus recommendation for the biotechnology & medical research peer group is also "Buy". Wall Street's median 12-month price target for vTv Therapeutics Inc is $35.00, above its last closing price of $16.68. This summary was machine generated March 7 at 13:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on vTv Therapeutics
See all newsBrief: Vtv Therapeutics Announces FDA Orphan Drug Designation For Hppd In Sickle Cell Disease
vTv Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
vTv Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
vTv Therapeutics Q2 net loss widens on higher trial costs
Brief: VTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)